HALO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Halozyme Therapeutics is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has strong underlying trend support and positive analyst coverage, but it is also overbought, lacks a recent news catalyst, has no strong proprietary buy signal today, and hedge funds are heavily selling. Given the current setup, the better call is to hold and wait for a cleaner entry rather than buying immediately.
HALO is in a bullish price trend: SMA_5 > SMA_20 > SMA_200 and MACD histogram is positive and expanding, which confirms upward momentum. However, RSI_6 is 80.938, which signals the stock is overbought and stretched in the near term. Price closed at 77.4 versus a previous close of 79.45, and it is trading near resistance at R1 78.208 with the next resistance at R2 81.156. The pivot is 73.437, so the trend is still constructive, but the current level is not an attractive beginner entry after a strong run.
Analysts remain constructive overall, with Morgan Stanley reiterating Overweight and H.C. Wainwright maintaining Buy. Guidance for 2026-2028 was reiterated and a new share repurchase program was announced, which supports the long-term thesis. Technical trend remains bullish, and option positioning is call-heavy. No negative news was reported in the past week.
There is no recent news catalyst to push the stock higher immediately. RSI is overbought, so the share price is stretched. Hedge funds are selling aggressively, with selling up 4215.85% over the last quarter. The stock trend model also points to a high probability of a short-term pullback, including an estimated -7.94% over the next week.
Latest quarterly financials were not provided because the financial snapshot returned an error, so a direct quarter-by-quarter growth assessment is not available. Based on analyst commentary, the company reported solid Q1 results and reiterated 2026-2028 guidance, which implies the latest quarter was stable enough to support outlook confidence. The latest quarter season referenced by analysts is Q1 2026.
Analyst sentiment is positive but slightly mixed on valuation expectations. Morgan Stanley lowered its price target from $96 to $93 while keeping Overweight, which is still bullish but shows some caution. H.C. Wainwright raised its target from $90 to $95 and kept Buy, citing expected royalty momentum re-acceleration. Morgan Stanley also previously raised its target from $94 to $96. Overall, Wall Street remains constructive, with a favorable long-term view, but recent target changes suggest expectations are being refined rather than aggressively upgraded.
